Anthony Drier

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

E. Wallen, M. Harrison, M. Milowsky, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).

E. Wallen, M. Harrison, M. Milowsky, 2021 .

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

E. Basch, M. Milowsky, William Y. Kim, 2018, British Journal of Cancer.

Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC).

I. Ostrovnaya, G. Iyer, M. Milowsky, 2016 .

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

E. Basch, M. Milowsky, William Y. Kim, 2018, British Journal of Cancer.

Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer.

G. Mayhew, M. Milowsky, William Y. Kim, 2019, Journal of Clinical Oncology.